Available Trials

The new medicine tested in this study is being developed as a potential treatment for patients with chronic fibrotic diseases. These are diseases associated with the thickening and scarring of connective tissue in an organ, often as the result of injury. The study drug has the potential to stop the disease development by obstructing the cell functions that drive fibrosis.

The aims of the study are to determine the safety of the study drug and any side-effects that might be associated; how much of the study drug gets into the bloodstream and how long it takes the body to remove it; and the effect of the study drug on the immune system by looking at the antibodies made by the body.

Volunteers will receive the study drug once in the form of an intravenous infusion in the arm.

This is a first time in human study.

The study drug is being developed by the sponsor as a treatment for a kidney disease.

The main purpose of the study is to see what happens when the study drug is given, including any side effects and how the study drug is absorbed, metabolised (chemically broken down), distributed through the body, and excreted (eliminated from the body).

This is a First Time in Man Study

The main purpose of the study is to see how safe the Study Drug is and how well it is tolerated after dosing.

The study will also investigate:

• How the Study Drug is taken up, metabolised (chemically broken down), distributed through the body and excreted, this is called the pharmacokinetics (PK) of the Study Drug.

• How the body is affected by the Study Drug, this is called the pharmacodynamics (PD) of the Study Drug.

• Try to understand why different people respond differently to the same drug through DNA testing (please refer to the separate informed consent form for genetic testing).The sponsor is developing the study drug as a treatment for asthma. Asthma is a chronic disease of the airways that makes breathing difficult. The study drug works by preventing the formation of certain proteins by the immune system, which cause inflammation (swelling), and so reducing the symptoms of asthma.

This is a first time in human study.

The sponsor is developing the study drug as a treatment for non-alcoholic steatohepatitis, a condition affecting the liver which can cause swelling, inflammation and ultimately irreversible damage as the condition worsens. The Study drug is also being developed to treat no-proliferative diabetic retinopathy, which is the earliest stage of eye disease cause by diabetes.

The main purpose of this study in healthy volunteers is to understand the effect of the study drug on the activity of a protein found in the brain, called Monoamine Oxidase B. This protein plays an important role in the brain by affecting the levels of substances which control the transmission of nerve signals. The study will also investigate how the study drug is taken up, metabolised, distributed through the body and excreted.

The drug being developed is for the treatment of certain immune system diseases.

The main purpose of the study is to determine the safety and of the drug and how well it is tolerated. Investigate how the drug is taken up, distributed and metabolised by the body. As well as to understand the effect of the drug on the immune system by looking at antibodies.

The drug is administered via subcutaneous injection or infusion.

This is a first-in-human study

The drug being developed is for the treatment of kidney disease and is administered as an IV infusion.

For this study we are looking to recruit healthy, non-smoking men and woman(of non-child bearing potential) aged 18-55 years with a BMI of 18.5-35 kg/m2.

The study consists of 3 x 3 night stays in the unit with a total of 13 outpatient visits. The total duration of the study is just under 4 months from first admission to final visit. Part payments will be paid.